JPRN-UMIN000018628尚未招募3 期
A study of Bortezomib therapy for antibody mediated rejection in kidney transplantation - A study of Bortezomib therapy for antibody mediated rejection in kidney transplantation
iigata University Medical and Dental Hospital0 个研究点目标入组 15 人开始时间: 2015年10月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Cardio-respiratory dysfunction, liver dysfunction (AST/ALT>2.5 times of upper limits), bone marrow dysfunction (neotrophil<1000/ul, platelet<75000), allergy of Bortezomib as well as disqualified recipients with the other reasons
研究者
相似试验
进行中（未招募）
不适用
Bortezomib as consolidation therapy in patients aged 60 years and younger with multiple myelomamultiple myeloma in patients aged 60 years and younger having been treated before initiation of the study with a high dosage chemotherapy with melphalane followed by an autologous or allogenic stemcell transplantationMedDRA version: 14.1Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-004948-31-DEJANSSEN-CILAG GmbH
进行中（未招募）
不适用
Bortezomib as consolidation therapy in patients aged 61-75 years with multiple myelomamultiple myeloma in patients aged 61-75 years having been treated before initiation of the study with a high dosage chemotherapy with melphalane followed by an autologous stemcell transplantationMedDRA version: 15.0Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-004947-73-DEJANSSEN-CILAG GmbH190
进行中（未招募）
不适用
Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethason followed by maintenance in primary refractory or relapsed bortezomib naïve multiple myeloma patientsEUCTR2008-004822-17-NLniversity Medical Center
已完成
2 期
Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethason followed by maintenance in primary refractory or relapsed bortezomib naïve multiple myeloma patientsM. Kahler.10018849Multiple myelomaNL-OMON38293niversitair Medisch Centrum Groningen73
进行中（未招募）
不适用
A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myelomaMedDRA version: 16.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2009-017903-28-FIHOVON Foundation1,500